In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma were randomized to receive a quadruplet induction and consolidation regimen incorporating isatuximab with carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) versus a control regimen of carfilzomib, lenalidomide, and dexamethasone (KRd) without isatuximab. The primary reporting note indicates that the Isa-KRd approach resulted in higher rates of measurable residual disease (MRD) negativity after consolidation compared with KRd.
The description specifies the use of pretransplant induction followed by post-transplant consolidation in the Isa-KRd arm, aligned with a transplant-eligible strategy for newly diagnosed disease. The summary provided does not include numerical MRD negativity rates, confidence intervals, overall survival, progression-free survival, adverse events, or safety comparisons.
Therefore, the exact magnitude of MRD improvement, statistical significance, and potential trade-offs remain unspecified in the available content. Clinicians should interpret the reported MRD advantage in the context of missing detailed quantitative results and without extrapolating beyond what is stated.
Nature Medicine published a clinical update in Research Highlights on 06 Apr 2026.
The item focuses on Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.
Review the original article for the full source wording and details.